 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revelation Biosciences GAAP EPS of -$0.25

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of...

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders (the Annual...

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

Revelation Biosciences (NASDAQ:REVB  Get Rating) and Deciphera Pharmaceuticals (NASDAQ:DCPH  Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation...

Revelation Biosciences (NASDAQ:REVB) & Deciphera Pharmaceuticals (NASDAQ:DCPH) Head-To-Head Review

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the...

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 financial results and highlighted...

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

The closed lower by around 80 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
read more...

Revelation Biosciences And 2 Other Penny Stocks Insiders Are Buying

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy...

Video: Thursday 4/20 Insider Buying Report: REVB, NTIC

Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy? Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy? PR Newswire NEW YORK, April 17, 2023 NEW YORK, April 17, 2023 /PRNewswire...

Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy?

Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its year end 2022 financial results and highlighted recent corporate...

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Watchers	3,014
52-Wk Low	$0.64
52-Wk High	$17.55

Market Cap	$4.31M
Volume (M)	18,656.00
52-Wk High	$17.55
52-Wk Low	$0.64

REVB Revelation Biosciences Inc

About

Feed

News

Sentiment

Fundamentals